Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

Summary

The purpose of this study is to characterize the effect of renal function on the PK of a 0.25 mg single oral dose of bevenopran in humans and to assess the safety and tolerability of bevenopran in patients with varying degrees of renal impairment and in healthy subjects.

Timeline

Start

2013-09

Primary completion

2013-12

Completion

2013-12

Outcome

Outcome not reported

Stopped: “Development of compound has been put on hold.”

Drugs

Indications